Medical diagnostics company Cytovale’s IntelliSep test has received US Food and Drug Administration (FDA) 510(k) clearance to aid in the early detection of sepsis.
IntelliSep is the first FDA-cleared diagnostic tool to assess cellular host response to aid in identifying emergency department (ED) patients with sepsis and contribute to life-saving decisions.
IntelliSep is a groundbreaking diagnostic tool that helps clinicians recognise sepsis and supports critical time-sensitive clinical decisions, providing test results in under 10 minutes. The first in a new class of ED-focused diagnostic tools that assess host response, the test is a simple, fast, and intuitive solution that provides actionable answers directly from a standard blood draw. IntelliSep categorises patients into three bands according to their probability of sepsis, with Band 1 indicating low probability of sepsis and Band 3 indicating high probability of sepsis. The results may equip providers with a tool to optimise clinical outcomes and empower hospitals to improve resource utilisation and achieve operational excellence. IntelliSep may also support hospital efforts to meet guidelines set by the Centers for Medicare & Medicaid Services (CMS) for timely sepsis treatment, known as SEP-1.
The risk of death from sepsis increases by as much as 8% each hour the condition goes untreated. According to the Sepsis Alliance, as many as 80% of sepsis deaths could be prevented with rapid diagnosis and treatment, making early detection critical to improving clinical, operational, and financial outcomes.
“Early detection of sepsis is an invaluable capability for healthcare professionals. Quickly identifying sepsis is critical to saving lives, but until now, we’ve lacked a reliable tool to either recognise the condition or explore alternate diagnoses,” said Hollis O’Neal, MD, Medical Director of Research at Our Lady of the Lake Regional Medical Center, Critical Care Physician at LSU Health Sciences Center, and National Principal Investigator on the multi-centre CV-SQuISH-ED study that supported the clearance. “IntelliSep is truly a game changer for sepsis because it provides a unique indicator that gets to the heart of the current sepsis definition, immune dysregulation. The test provides hospital staff with the information needed to identify and treat septic patients efficiently and reduce the financial and health burdens of overtreatment for hospitals and patients.”
The CV-SQuISH-ED study is a multi-centre clinical validation study that was completed in early 2022 and is being prepared for publication. Data from previously published studies demonstrate the 10-minute test’s potential to aid physicians in rapidly identifying patients at increased risk of sepsis.
IntelliSep’s innovative technology, which is run on the Cytovale System, assesses the body’s immune response to an infection using immune cell morphology. By applying pressure to tens of thousands of cells and observing their reaction, IntelliSep can provide valuable new insight related to sepsis. The biophysical properties of white blood cells from septic patients demonstrate distinct changes when subjected to pressure; these changes are captured in images and then characterised using a proprietary algorithm to produce a result.
